Natera (NTRA) anticipates 2025 total revenue of $2.18 billion – $2.26 billion; 2025 gross margin to be approximately 62% to 64% of revenues; selling, general and administrative costs to be approximately $1.08 billion to $1.18 billion; research and development costs to be approximately $575 million to $625 million; and net cash inflow to be approximately $100 million.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera announces data from PROCEED-CRC trial
- Natera Inc.’s New Prenatal Test Study: A Potential Game-Changer in Genetic Screening
- Natera’s New Study: A Potential Game-Changer in Breast Cancer Treatment
- Natera’s FIND-CRC Study: A Potential Game-Changer in Colorectal Cancer Screening
- Natera Inc.’s Innovative Approach to Heart Transplant Rejection Monitoring: A Study Update